{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:27:40Z","timestamp":1786116460841,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007408","name":"University of Pittsburgh Medical Center","doi-asserted-by":"publisher","award":["STUDY22070065"],"award-info":[{"award-number":["STUDY22070065"]}],"id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Carbapenem-resistant Enterobacterales (CRE) are classified as carbapenemase- and non-carbapenemase-producing (non-CP) CRE. The purpose of this study was to identify factors associated with meropenem non-susceptible non-CP CRE to help stratify treatment approaches and to report rates of treatment-emergent resistance among patients with non-CP CRE bacteraemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, single-centre study of patients hospitalized between January 2015 and September 2025 with bacteraemia due to Enterobacterales resistant to ertapenem and confirmed to be non-CP. Ertapenem resistance was determined by broth microdilution susceptibility testing. Carbapenemase testing was performed by modified carbapenem-inactivation method, polymerase chain reaction or whole-genome sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 60 patients who met the inclusion criteria, the median (IQR) age was 63\u2005years (57\u201373), 33% (20\/60) were female and 18% (11\/60) were organ transplant recipients. Patients infected with meropenem non-susceptible non-CP CRE were more likely to have prior meropenem exposure [60% (10\/15) versus 13% (8\/45), P\u200a&amp;lt;\u200a0.001] and have breakthrough bacteraemia [60% (9\/15) versus 29% (13\/45), P\u200a=\u200a0.031]. Treatment-emergent resistance developed in 16% (4\/24) and 0% (0\/15) of patients treated with meropenem and ceftazidime-avibactam, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These exploratory data provide new insights into clinical factors associated with meropenem non-susceptible non-CP CRE and support future investigations into the comparative-effectiveness of meropenem versus beta-lactam\/beta-lactamase inhibitors for the treatment of meropenem-susceptible non-CP CRE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag267","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:07:32Z","timestamp":1784722052000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and outcomes of patients with bacteraemia caused by non-carbapenemase-producing, carbapenem-resistant\n                    <i>Enterobacterales<\/i>"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1451","authenticated-orcid":false,"given":"Sunish","family":"Shah","sequence":"first","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Falk Medical Building, Suite 3A, Room 317, 3601 Fifth Avenue, Pittsburgh, PA 15213 ,","place":["USA"]},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd G","family":"Clarke","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Falk Medical Building, Suite 3A, Room 317, 3601 Fifth Avenue, Pittsburgh, PA 15213 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7167-6368","authenticated-orcid":false,"given":"Ellen G","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel V","family":"Marini","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Falk Medical Building, Suite 3A, Room 317, 3601 Fifth Avenue, Pittsburgh, PA 15213 ,","place":["USA"]},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Squires","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Falk Medical Building, Suite 3A, Room 317, 3601 Fifth Avenue, Pittsburgh, PA 15213 ,","place":["USA"]},{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026080606044285200_dkag267-B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/jac\/25.1.49","article-title":"Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenes","volume":"25","author":"Hopkins","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2026080606044285200_dkag267-B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026080606044285200_dkag267-B3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab643","article-title":"Distinctive features of ertapenem-mono-resistant carbapenem-resistant Enterobacterales in the United States: a cohort study","volume":"9","author":"Adelman","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026080606044285200_dkag267-B4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/jac\/dkae186","article-title":"Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales","volume":"79","author":"Weston","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026080606044285200_dkag267-B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106439","article-title":"Activity of ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals","volume":"58","author":"Castanheira","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2026080606044285200_dkag267-B6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Multi-drug resistant organism network investigators. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026080606044285200_dkag267-B7","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1017\/ash.2026.10348","article-title":"The changing epidemiology and long-term outcomes of patients with CRE infections","volume":"6","author":"Shah","year":"2026","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026080606044285200_dkag267-B8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1128\/JCM.00193-17","article-title":"Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae","volume":"55","author":"Pierce","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2026080606044285200_dkag267-B9","author":"CLSI"},{"key":"2026080606044285200_dkag267-B10","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080606044285200_dkag267-B11","author":"R Core Team"},{"key":"2026080606044285200_dkag267-B12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41598-023-51118-9","article-title":"Comparison of mortality rates in patients with carbapenem-resistant Enterobacterales bacteremia according to carbapenemase production: a multicenter propensity-score matched study","volume":"14","author":"Baek","year":"2024","journal-title":"Sci Rep"},{"key":"2026080606044285200_dkag267-B13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026080606044285200_dkag267-B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115505","article-title":"Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia","volume":"101","author":"Hovan","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026080606044285200_dkag267-B15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/antibiotics12010102","article-title":"In vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales","volume":"12","author":"Bonnin","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026080606044285200_dkag267-B16","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00137-24","article-title":"The American Society for Microbiology's evidence-based laboratory medicine practice guidelines for the diagnosis of bloodstream infections using rapid tests: a systematic review and meta-analysis","volume":"38","author":"Wolk","year":"2025","journal-title":"Clin Microbiol Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag267\/70505445\/dkag267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag267\/70505445\/dkag267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:04:49Z","timestamp":1786010689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag267\/8753071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag267","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag267"}}